Clinical Trials Logo

Clinical Trial Summary

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.


Clinical Trial Description

A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04338659
Study type Interventional
Source Innovent Biologics (Suzhou) Co. Ltd.
Contact
Status Completed
Phase Phase 1
Start date January 14, 2021
Completion date February 28, 2023